Biocartis and Hospital del Mar Join Forces
News Oct 21, 2013
Biocartis and Hospital del Mar have announced their license agreement on the EGFR biomarker for colon cancer.
This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalized therapy.
Innovative platforms and tests for cancer diagnosis
Biocartis is active in molecular diagnostics and develops innovative diagnostic platforms, which allow for efficient disease detection. Biocartis also develops a wide range of clinically relevant tests for various therapeutic areas with a primary focus on cancer diagnosis.
EGFR: new biomarker for colon cancer
Recently Dr Montagut and her team (Dr Albanell’s department of Medical Oncology, Hospital del Mar) showed that colon cancer patients with an S492R-mutation in the EGFR (Epidermal Growth Factor Receptor) can’t be helped with the colon cancer drug cetuximab.
The EGFR mutation makes the tumours resistant to this treatment, whilst they remain sensitive to treatment with panitumumab. These results were published in the leading scientific journal Nature Medicine.
Rapid diagnosis results in personalized therapy
"Our agreement with Biocartis represents a crucial step in translating our relevant scientific findings to benefit the patient,” according to Clara Montagut, associated doctor, Oncology department, Hospital del Mar and researcher at the IMIM (Hospital del Mar Medical Research Institute).
The collaboration with Hospital del Mar enables Biocartis to develop a colon cancer test for a fast and accurate detection of the EGFR mutation.
"This new biomarker enables us to develop a unique combination of tests for the detection of colon cancer, which can be analyzed on our state-of-the-art molecular diagnostic platforms," added Geert Maertens, Chief Scientific Officer at Biocartis.
Maertens continued, “The detection of this biomarker in colon cancer patients ensures that personalized therapy can be applied faster and more efficiently.”
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE